0001645113-26-000038
SEC filingNovoCure disclosed compensation terms for CEO Frank Leonard, including base salary, bonus, equity, severance, and tax indemnification, in an 8-K/A amendment.
This 8-K/A amendment provides the compensation details for Frank Leonard's appointment as CEO, which were not finalized at the time of the initial 8-K filing. The agreement includes a base salary of CHF 750,000, a target bonus of 90% of base salary, and eligibility for equity awards. Severance provisions are standard for a public company CEO: 100% of base salary for a non-change-in-control termination, and 200% of base salary plus 200% of target bonus for a termination within 12 months following a change in control, with full equity vesting. Notably, the agreement includes a tax indemnification clause for Leonard as a U.S. citizen working in Switzerland, protecting him from incremental tax liabilities if foreign tax credits are disallowed. This is a significant retention and compensation cost for the company. The filing also discloses relocation and COBRA expense reimbursements, grossed up for taxes. The non-compete and non-solicit covenants extend 12 months post-employment, which is typical for executive agreements.